Fibrillin-1 is a novel ligand of the epidermal growth factor receptor promoting mesangial cell activation and glomerulosclerosis doi.org/10.1016/j.kint.2026.01.018 #MedSky #NephSky #glomerulosclerosis

Clinical Applications of Artificial Intelligence in Autosomal Dominant Polycystic Kidney Disease @ndt-era.bsky.social oup2-idp.sams-sigma.com/authorize?au...

New findings suggest a steady increase in the prevalence of kidney failure with replacement therapy worldwide over the past 3 decades. Read more in #ASNKidneyNews kidney.pub/KN1710-24#ASNKidneyNews

2025 AJKD Editors' Choice Award winning article: Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study bit.ly/3WeEZ72 #VisualAbstract

📖 This weekend don't miss our @kidneyint.bsky.social #ISNFridaySelection: Patient preferences for kidney failure treatments www.kidney-internati...

Register for our upcoming webinar in 2026✨ 📌Registration is FREE www.eeds.com/portal_live_...

Artificial Intelligence in ADPKD: Transforming Diagnosis, Risk Stratification, and Therapeutic Interventions SA-PO0555 : Journal of the American Society of Nephrology #KidneyWk journals.lww.com/jasn/fulltex...

Did you know Women in Nephrology offers a Mentor Match program? Whether you want to be a mentor or find one, WIN helps you connect with your perfect match. If you are a member, apply today! #WIN #MentorMatch

Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (#IgAN) and Immunoglobulin A Vasculitis (#IgAV) doi.org/10.1016/j.kint.2025.04.003 #OpenAccess #MedSky #NephSky @kdigo.org

Core Curriculum by Craig E. Gordon et al: Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025 bit.ly/465twwK (FREE)

Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/41105470/

Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...

Thank you NKF for having us at the #NKFSoCalKidneyWalk 🧡 Today, we hosted a booth to recruit for our “Kidney Check” study, proudly sponsored by the IgAN Foundation.

IgG4-related tubulointerstitial nephritis with negative contrast-enhanced computed tomography: diagnostic insights from 18F-fluorodeoxyglucose–positron emission tomography/computed tomography doi.org/10.1016/j.kint.2025.02.031 #KINephrologyImage #NephSky #MedSky #KidneyPath #RenalPath #kidneybiopsy

ALECT2 amyloidosis in a patient with myeloma cast nephropathy Concomitant renal amyloidosis, typically AL, can be rarely seen in patients with myeloma cast nephropathy. doi.org/10.1016/j.kint.2024.12.024 #NephSky #MedSky #NephrologyImage #renalpath #kidneypath #kidneybiopsy #multiplemyeloma

Artificial intelligence and perspective for rare genetic kidney diseases Chen et al. doi.org/10.1016/j.kint.2025.03.033 #OpenAccess #KIMiniReview #artificialintelligence Find more articles in KI Kidney Genomic Medicine collection: www.kidney-international.org/content/kidn...

Executive summary of the #KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy ( #IgAN) and Immunoglobulin A Vasculitis ( #IgAV) doi.org/10.1016/j.kint.2025.04.003 #OpenAccess #MedSky #NephSky #glomerulardisease @imperialcollegeldn.bsky.social

The one and only @kidneyboy.bsky.social representing #NephJC at #GlomConHawaii 🌊 #NephSky

Is hepatotoxicity still a concern with long-term Tolvaptan use? This #ASNKidney360 review summarizes the data from clinical trials and presents real world evidence: kidney.pub/KID0934#ASNKidney360

Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy doi.org/10.1016/j.kint.2025.05.028 #OpenAccess #IgAN #felzartamab #IgANephropathy

Cardiovascular Complications in Autosomal Dominant Polycystic Kidney Disease - Kidney International Reports @kireports.bsky.social www.kireports.org/article/S246...

Amir Abdipour from #LomaLindaUniversityMedicalCenter discusses his study on the alignment of AI models with nephrologists when answering patient questions about #diabeticnephropathy. Watch now: www.youtube.com/watch?v=yqDP... Read the full article: diabetes.jmir.org/2025/1/e65846/ #AI #LLU

Watch this one-minute video highlighting our paper published in @jmirpub.bsky.social www.youtube.com/watch?v=yqDP...

Long-term data presented at #ERA25 on Thursday support the efficacy and safety of zigakibart for IgAN. #nephrology #nephsky #iganephropathy #igan www.docwirenews.com/post/long-te...

Only two weeks left❗️ Mark your calendar ✔️and register today. #EndPKD www.eeds.com/portal_live_...

Real-world challenges in the use of tolvaptan for ADPKD lead to high discontinuation rates and dosage adjustments, underscoring the need for standardized and improved management strategies to enhance tolerability and adherence. https://bit.ly/KID0816 @shelliefravel.bsky.social #ASNKidney360

📣Exciting News! We are thrilled to announce our upcoming Loma Linda Polycystic Kidney Disease Webinar: Expert Insights on Navigating the KDIGO 2025 ADPKD Guidelines. ✅FREE Registration 📅Friday, June 6, 2025 🕥 8:30 AM - 1:00 PM (Pacific Time) 🔗Register here: www.eeds.com/portal_live_...

New JMIR Diabetes: Agreement Between AI and Nephrologists in Addressing Common Patient Questions About Diabetic Nephropathy: Cross-Sectional Study

Applications are now open for the Polycystic Kidney Disease Medical Directorship Program (PKD-MDP)! 🤩 🔗 Apply here: www.glomcon.org/pkdmd-program 📅 Deadline to apply is July 15, 2025

In our upcoming webinar, you’ll learn... ➡️ How ADPKD is diagnosed and what to monitor ➡️ Factors that impact disease severity ➡️ The genetics of ADPKD and when genetic testing is recommended ➡️ Ethical considerations and family planning Register today at bit.ly/3XHwsuS

The FDA has approved Amgen’s Uplizna to help reduce risk of flares in adults with IgG4-RD, a rare immune system-related chronic condition that can lead to inflammation & scarring of organs including the kidneys. The first treatment approved for IGG4-related disease: www.healio.com/news/rheumat...

PKD affects us all in different ways, but together, we are stronger. Show the world your connection to polycystic kidney disease by sharing one of these graphics. Whether you're living with PKD or caring for a loved one, we’re all fighting for a future without it.

This study found that waitlist experience, allograft quality, and post-transplant outcomes of patients with ADPKD are influenced by patient race. bit.ly/CJASN0626 #ASNCJASN

These clinical trials are the first to demonstrate increased polycystin 1 and 2 levels and decreased htTKV in ADPKD patients—critical factors supporting further Phase 2/3 trials. Read more about their findings at www.prnewswire.com/news-release...

These findings align with the Phase 2a trial results presented last October at the American Society of Nephrology’s Kidney Week Conference. Over 16 weeks, this study found that patients receiving 3mg/kg farabursen saw a 0.6% decrease in htTKV, compared to a 2.5% increase in those on a placebo.

➡️ Increased levels of the proteins polycystin 1 and 2 in patients’ urine (which could slow or reverse cyst growth)  ➡️ Notable decrease in height-adjusted total kidney volume (htTKV), a way to measure disease progression based on kidney volume and a patient’s height/age.

Regulus recently announced promising interim results from their Phase 1b trial of farabursen (RGLS8429) as a possible treatment for ADPKD! In their latest analysis of 14 patients (who received fixed 300mg doses) from their fourth study group, there were two important observations ⬇️

storage.unitedwebnetwork.com/files/1099/5... #ISNWCN 2025 🇮🇳 @theisn.org @isnkidneycare.bsky.social

⭐️The First International Hybrid Glomerular Diseases Conference: GlomCon Hawaii ⭐️ Now Published 👇#NephSky #glomlovers @glomcon.org 🚨pubmed.ncbi.nlm.nih.gov/39827877/

Effective patient-physician communication to improve health-related quality of life and adherence to treatment plan⭐️ See our recent paper @JournalofNeph link.springer.com/article/10.100…#Nephskyky

Huge thanks to our faculty, supporters, and attendees for making the Rare Kidney Disease Conference a success! As ⭐️Dr. Glassock highlighted bridging research and clinical practice is essential for improving patient care. Love our neph community ❤️ It’s such a fantastic time to be a nephrologist.

Interested in exploring the physiology of diabetic nephropathy? #Glomlovers ⭐️Check out the latest issue of KidneyNews featuring insightful contributions from my talented mentees, Niloufar and Saloni our LLU and @glomcon.org fellow ⭐️ @kdjhaveri.bsky.social kidneynews.org/view/journals/…

Special issue Dec 2024 Kidney News The Glomerulus Chronicles: Diabetic Nephropathy Unveiled -- Niloufar Ebrahimi, Saloni Gupta @saynanorouzi.bsky.social kidneynews.org/view/journal... @asnkidney.bsky.social

We've nearly reached 400 registrations, with 130 attending in person! There's still time to sign up. 👇 eeds.com/portal_live_ev… I can hardly believe it's happening this weekend. Plus, the weather in Palm Springs is looking perfect#Excitede#GlomLoversrs @glomcon.org

Covering consults today, and look what I got in the mail! Happy Thanksgiving, @ajkd.bsky.social 😄🤩

Thank you Docwire for highlighting our upcoming Rare Kidney Disease conference. docwirenews.com/post/loma-li... Almost 350 registrations; 121 in-person Still have time to register here 👇 www.eeds.com/portal_live_...

Glomerular disease combined with case-based teaching? Count me in! 😄 It's my favorite part of @ajkd.bsky.social Check out this fascinating GN case here: ajkd.org/article/S0272-…

Our registration stats so far for the upcoming Rare Kidney Disease conference 312 total registrations 105 in-person 😍🤩 Really excited!! You still have time to register👇 It’ll get recorded and you will have access to the content up to 6 months!! www.eeds.com/portal_live_...

After launching our PKD clinic, we noticed a gap in care—many high-risk PKD patients aren’t aware of Tolvaptan.. We created a survey to identify barriers. Check out the results in our latest paper👇⭐️📄💡 Grateful to work with the experts on this paper! link.springer.com/article/10.1...